证券代码：300009 证券简称：安科生物 公告编号：2025-047 安徽安科生物工程（集团）股份有限公司 关于公司监事辞职的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于近日收到 公司监事李城花女士的辞职报告，李城花女士因个人原因辞去职工代表监事职务， 辞职后不再担任公司其他任何职务。 李城花女士在担任公司监事期间勤勉尽责，公司及公司监事会对李城花女士 在任职期间为公司所做出的积极贡献予以衷心感谢。 特此公告。 安徽安科生物工程（集团）股份有限公司 监事会 2025 年 08 月 21 日 根据《公司法》等相关法律法规和《公司章程》的规定，李城花女士的辞职 将导致公司监事会成员低于法定最低人数。按照《公司法》等相关规定，李城花 女士将继续履行监事职责。李城花女士的辞职不会影响公司及监事会的正常运作。 公司将按照相关规定尽快做出调整，使公司的组织架构适应公司发展规划，符合 《公司法》等法律法规要求的法人治理规则。 李城花女士原定任期为 2022 年 12 月 23 日至 2025 年 12 月 2 ...

安徽安科生物工程（集团）股份有限公司 监事会关于公司第三期限制性股票激励计划相关事项的 根据《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》等有关法 律、法规、规范性文件和《安徽安科生物工程（集团）股份有限公司章程》的规 定，安徽安科生物工程（集团）股份有限公司（以下简称"公司"）监事会于 2025 年 8 月 20 日召开第八届监事会第十九次会议，审议通过了《关于回购注销部分 限制性股票的议案》，对公司第三期限制性股票激励计划（以下简称"本次激励 计划"）回购注销部分限制性股票事项进行了核查，并发表核查意见如下： 经核查，同意公司根据《第三期限制性股票激励计划（草案修订稿）》的相 关规定，回购注销不再具备激励资格的激励对象已获授但尚未解除限售的全部限 制性股票。本次将以激励对象购买价格回购限制性股票并注销，其中：首次授予 部分回购价格为 4.81 元/股，回购注销的限制性股票数量为 174,000 股；预留授 予部分回购价格为 5.27 元/股，回购注销的限制性股票数量为 102,500 股，回购 资金为公司自有资金。本次回 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-044 安徽安科生物工程（集团）股份有限公司 关于第八届监事会第十九次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第八届监事 会第十九次会议于 2025 年 8 月 10 日以书面形式发出会议通知，2025 年 8 月 20 日上午 11:00 以现场会议的方式召开。应参会监事 3 人，实际参会监事 3 人。本 次会议的召开与表决程序符合《公司法》和《公司章程》等的有关规定，会议由 监事会主席李增礼先生主持。 经与会监事充分讨论，表决通过如下决议： 一、以 3 票赞成，0 票反对，0 票弃权审议通过了《<公司 2025 年半年度报 告>及其摘要》 同意公司根据相关规定回购注销不符合激励条件的第三期限制性股票激励 计划激励对象已获授但尚未解除限售的全部限制性股票，本次回购注销完成后， 公司第三期激励计划将继续按照法规要求执行。具体内容详见同日刊登在中国证 监会指定信息披露网站巨潮资讯网的《监事会关于公司第三期限制性股票激励计 划 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-043 安徽安科生物工程（集团）股份有限公司 关于第八届董事会第二十一次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据相关规定，公司 2025 年半年度报告摘要将同时刊登于 2025 年 8 月 22 日的《中国证券报》《上海证券报》《证券时报》。 本议案以12票同意、0票反对、0 票弃权获得通过。 2、审议通过《关于回购注销部分限制性股票的议案》 根据《公司第三期限制性股票激励计划（草案修订稿）》（以下简称《第三期 激励计划》）的规定，及公司2022年第二次临时股东大会授权，同意公司回购注 销不符合激励条件的激励对象已获授但尚未解除限售的276,500股限制性股票， 占公司现有总股本的0.02%。具体内容详见同日刊登在中国证监会指定信息披露 网站巨潮资讯网的《关于回购注销第三期限制性股票激励计划部分限制性股票的 公告》（公告编号：2025-045）。 公司董事会薪酬与考核委员会已对本次回购注销事项进行了核查并事前审 议通过，一致同意将本议案提交董事会审议。 本议案以12票同意、 ...

安徽安科生物工程(集团)股份有限公司 2025 年半年度报告全文 1 安徽安科生物工程(集团)股份有限公司 2025 年半年度报告全文 安徽安科生物工程(集团)股份有限公司 2025 年半年度报告 公告编号：2025-041 【2025 年 8 月 22 日】 2 安徽安科生物工程(集团)股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人宋礼华、主管会计工作负责人胡成浩及会计机构负责人(会计 主管人员)胡成浩声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来计划等前瞻性陈述不构成公司对投资者的实质承诺， 敬请投资者理性投资，注意风险。 报告期内，公司可能存在新药研发不达预期的风险、行业政策变化及集中 带量采购导致药品降价的风险、业务整合及规模扩大带来的集团化管理风险、 投资项目收益不达预期的风险等，有关风险因素内容详见本报告中第三节"管 理层讨论与分析"之 ...

Core Insights - The company Anke Bio announced a revenue of 1.292 billion yuan for the first half of 2025, representing a year-on-year decrease of 0.51% [1] - The net profit for the same period was 367 million yuan, showing a year-on-year decline of 11.92% [1] Financial Performance - Revenue: 1.292 billion yuan, down 0.51% year-on-year [1] - Net Profit: 367 million yuan, down 11.92% year-on-year [1]

Group 1 - The assisted reproductive concept sector declined by 0.81%, ranking among the top declines in concept sectors, with major declines seen in companies like Fuyuan Pharmaceutical, Guangsheng Tang, and Wanfu Biology [1][2] - Among the 59 stocks in the assisted reproductive sector, 23 stocks saw price increases, with notable gains from Toukeng Life (up 7.45%), ST Xiangxue (up 4.55%), and Sichuan Shuangma (up 3.55%) [1][2] - The assisted reproductive sector experienced a net outflow of 2.015 billion yuan in main funds, with Guangsheng Tang leading the outflow at 297.48 million yuan [2][3] Group 2 - The top stocks with net outflows in the assisted reproductive sector included Guangsheng Tang, Hanyu Pharmaceutical, and Fuyuan Pharmaceutical, with outflows of 297.48 million yuan, 212.23 million yuan, and 164.10 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Wuchan Zhongda, Sichuan Shuangma, and Xianju Pharmaceutical, with inflows of 59.78 million yuan, 52.71 million yuan, and 36.47 million yuan respectively [2][4] - The overall trading activity in the assisted reproductive sector showed significant turnover rates, with Guangsheng Tang at 12.48% and Hanyu Pharmaceutical at 19.69% [2][3]

Core Viewpoint - The hepatitis concept sector experienced a decline of 0.67%, with several companies facing significant losses, while a few companies saw gains, indicating a mixed performance in the market [1]. Group 1: Sector Performance - The hepatitis concept sector ranked among the top decliners, with companies like New Tian Pharmaceutical and Chengyi Pharmaceutical hitting the daily limit down [1]. - Notable decliners included Guangshantang and Weikang Pharmaceutical, while Renhe Pharmaceutical, Fangsheng Pharmaceutical, and Lifang Pharmaceutical were among the few that saw gains, with increases of 10.00%, 9.99%, and 4.76% respectively [1]. Group 2: Capital Flow - The hepatitis concept sector saw a net outflow of 2.295 billion yuan, with 95 stocks experiencing net outflows, and 7 stocks seeing outflows exceeding 100 million yuan [2]. - The stock with the highest net outflow was Furuishi, with a net outflow of 484.35 million yuan, followed by Guangshantang and Hanyu Pharmaceutical with outflows of 297.48 million yuan and 212.30 million yuan respectively [2]. Group 3: Individual Stock Performance - Furuishi's stock declined by 1.29% with a turnover rate of 21.35% and a significant net outflow of 484.35 million yuan [2]. - Guangshantang's stock fell by 8.69% with a turnover rate of 12.48% and a net outflow of 297.48 million yuan [2]. - Chengyi Pharmaceutical saw a decline of 9.99% with a turnover rate of 16.81% and a net outflow of 581.07 million yuan [3].

Market Overview - The biopharmaceutical sector increased by 0.27% on August 19, with Olin Bio leading the gains [1] - The Shanghai Composite Index closed at 3727.29, down 0.02%, while the Shenzhen Component Index closed at 11821.63, down 0.12% [1] Top Performers - Olin Bio (688319) closed at 31.21, up 12.71% with a trading volume of 275,600 shares and a transaction value of 831 million [1] - Nossland (430047) closed at 28.44, up 11.53% with a trading volume of 211,700 shares and a transaction value of 622 million [1] - Ganli Pharmaceutical (603087) closed at 68.03, up 6.95% with a trading volume of 406,100 shares and a transaction value of 2.793 billion [1] Underperformers - Junshi Biosciences (688180) closed at 45.32, down 3.70% with a trading volume of 210,400 shares and a transaction value of 977 million [2] - ZhiXiangQuanTai (688443) closed at 33.05, down 3.42% with a trading volume of 77,200 shares and a transaction value of 260 million [2] - SanShengGuoJian (688336) closed at 54.10, down 2.50% with a trading volume of 85,900 shares and a transaction value of 477 million [2] Capital Flow - The biopharmaceutical sector saw a net inflow of 250 million from institutional investors, while retail investors experienced a net outflow of 379 million [2][3] - Major stocks like Shenzhou Cell (688520) had a net inflow of 1.39 billion from institutional investors, but a net outflow of 1.08 billion from retail investors [3]

Group 1 - A-shares entered a concentrated disclosure period for mid-term reports, with public fund research enthusiasm rising significantly, as 139 public fund institutions participated in A-share research activities last week, covering 66 stocks across 20 Shenwan primary industries, with a total of 729 research instances, representing a week-on-week increase of 46.39% [1][2] - The leading stock in the beauty and personal care sector, Baiya Co., was the most researched, with 53 instances of public fund research, attracting over 30% of public fund institutions including Bosera Fund, Harvest Fund, and China Merchants Fund [1][2] - The pharmaceutical and biological sector received high attention from public fund institutions, with three stocks making the top ten in research instances: Nanwei Medical (46 times), Anjiasi (32 times), and Anke Biological (32 times) [1][2] Group 2 - The computer industry also saw significant interest, with two stocks in the top ten: Desai Xiwai (46 times) and Jinchengzi (45 times) [1][2] - The pharmaceutical and biological sector was the most favored by public fund research, with a total of 10 stocks receiving attention, accumulating 151 research instances, leading other industries in both the number of researched stocks and research instances [2] - Other industries such as electronics, electric equipment, basic chemicals, and beauty care also received attention, with each being researched at least 50 times, ranking in the top ten [3] Group 3 - Among institutions, Penghua Fund led with 20 research instances covering 19 stocks across 11 industries, with a relatively high proportion in electric equipment, electronics, and basic chemicals [3] - Guotai Fund and Southern Fund both ranked second with 14 research instances each, focusing on different sectors, with Guotai Fund emphasizing pharmaceutical and biological stocks, while Southern Fund covered a broader range including electronics, computers, electric equipment, and basic chemicals [3]